INTRODUCTION
Obstetric and gynecological hemorrhage remains a frequent and severe complication that affects women at childbearing age and at the period of their full physical and professional activity. This problem applies to women in both developing and industrial countries. In the latter ones, including Poland, it is a result of constantly increasing rate of caesarean deliveries, accompanied by a several times higher risk of peripartum hemorrhage. For the experts from the World Health Organization there is a target to limit the global maternal mortality ratio from 216 per 100 000 live births in 2015 to 70 per 100 000 live births in 2030 (World Health Statistics 2018. Indicator 3.1.1). Decrease in the incidence of severe hemorrhages and their consequences can be achieved through providing medical care by the health care professionals who have knowledge about the causes, pathomechanism and pharmacotherapy of these complications. It is known, that the development, implementation and compliance with management algorithms for severe hemorrhages contributes to a significant reduction in the number of organ complications and mortality. According to the knowledge of the authors of this paper, acquired hemophilia A is considered relatively rare as a cause of severe hemorrhage in gynecology and obstetrics.
Acquired hemophilia A (AHA) is an autoimmune disease caused by autoantibodies that impair the function of coagulation factor VIII (FVIII) and lead to a decrease in plasma FVIII activity. These antibodies are referred to as the circulating FVIII anticoagulant or FVIII inhibitor. Unlike congenital hemophilia A, with underlying mutation in the F8 gene located on the sex chromosome X, affecting males, acquired hemophilia A occurs in both men and women. Decrease in FVIII activity in the course of AHA results in a tendency to excessive bleeding.
Although acquired hemophilia A is classified as a severe bleeding disorder, in about 20-30% of cases it is initially manifested by only a minor bleeding, which often can even escape the attention of the physician [1] . However, it should be clearly stated, that as long as an FVIII inhibitor is detected in the patient's blood, the patient is at risk of experiencing a severe, potentially life-threatening hemorrhage.
Modern medicine has the effective tools to fight AHA, that enable control of bleeding, elimination of the inhibitor and reduction in mortality. Estimated mortality in the course of AHA in the 1980s reached up to 42%, while currently it does not exceed 12% [2] .
The present paper discusses the principles of AHA diagnosis, the usage of hemostatic agents for bleeding control and prevention, eradication of FVIII inhibitor and patients' surveillance after achieving remission. Particular attention was paid to gynecological-obstetrics aspects related to the diagnosis and treatment of female patients with AHA.
PATHOPHYSIOLOGY OF ACQUIRED HEMOPHILIA A
The key problem in AHA are disorders of the immune system resulting in the production of antibodies that neutralize coagulant activity of factor VIII [3] . The mechanisms responsible for the breakdown of immune system in AHA have not been fully elucidated. The result of deficiency or complete absence of FVIII in the plasma is inhibition of thrombin generation and the lack of fibrin clot formation in sites of the vascular wall damage, which manifests as bleeding or hemorrhage.
The autoantibodies produced in acquired hemophilia A are mostly IgG1 and IgG4 class and bind to FVIII epitopes located on its C2 and A2 domains. The mechanism of their anticoagulant action relies on impairment of FVIII interac-tion with phospholipids (anti-C2 antibodies), disturbances in the formation of the intrinsic tenaze complex (anti-A2 antibodies) and most likely also on blocking the binding of FVIII to von Willebrand factor [3, 4] .
The kinetics of FVIII interaction with autoantibodies in AHA is different from the kinetics of FVIII interaction with alloantibodies in congenital hemophilia A with inhibitors. While in congenital hemophilia A, alloantibodies completely abolish the FVIII activity in plasma, in acquired hemophilia A, even with a very high titer of autoantibodies, some residual plasma FVIII activity is detected. However, it does not protect AHA patients from severe bleeding [5] . Similarly to the FVIII alloantibodies, also autoantibodies to FVIII do not bind complement and do not cause allergic reactions.
EPIDEMIOLOGY
The annual incidence of acquired hemophilia A is estimated at approximately 1.5 per million [6, 7] . The incidence of AHA increases with age, amounting to approximately 0.045/million among children under 16 and 14.7/million in people over 85 years of age [6] . The results of the multi-center, large-scale, pan-European, Web-based Registry EACH2 (European Acquired Hemophilia Registry) published several years ago, showed that the median age at the time of diagnosis of AHA is 73.9 years. In the age range of 20-40 years, acquired hemophilia A is more often detected in women than in men [8] . The increased incidence of AHA among young women is closely related to the period of pregnancy, especially to the first 6-12 months after delivery (see below -Acquired hemophilia associated with pregnancy and delivery A). In the older age groups, AHA is slightly more often detected in men [1] .
Approximately half of patients with detectable autoantibodies against FVIII do not have underlying disorders. This form of AHA is called idiopathic. In approximately 35-40% of cases, AHA is associated with autoimmune disease, solid malignant tumors, hematologic tumors, allergic diseases or with a drug exposure (Tab. 1). The remaining 10-15% of cases of acquired hemophilia A are detected, as already mentioned, among others, in young women up to 12 months after delivery.
CLINICAL MANIFESTATION
In most cases, AHA manifests as a sudden severe bleeding disorder which can lead to the death of a patient within a few weeks [1, 9] . Unlike congenital hemophilia A, spontaneous bleeding to the joints is very rare in AHA. Typical for acquired hemophilia A are large subcutaneous hematomas ( Fig. 1) , mucosal bleeding (from the gastrointestinal and genitourinary tract), as well as bleeding from the wounds after surgical procedures and after tooth extraction (Tab. 2). It is worth noting that in AHA patients the most difficult to treat are hemorrhages from the wounds after surgical procedures. Therefore, invasive diagnostic and therapeutic procedures should be avoided in AHA patients [10] . Intracranial hemorrhages have a dramatic course and usually fail to be stopped on time. Fortunately, this type of bleeding is quite rare in patients with AHA. Bleeding to the extremity muscles is very dangerous, because hematoma, located in a fascia-limited anatomical space, may exert a pressure on nerves and blood vessels causing their irreversible injury.
ACQUIRED HEMOPHILIA A ASSOCIATED WITH PREGNANCY AND DELIVERY
Acquired hemophilia A is a rare complication of pregnancy and postpartum period. It is estimated that there is no more than one case of AHA in 350 000 deliveries [7] . The disease may occur immediately after delivery, manifested by a severe uterine or vaginal hemorrhage, as well as develop up to 12 months after delivery, with extensive subcutaneous hematomas as the predominant symptom, accompanied by the more or less severe mucosal hemorrhages. The Italian Registry data, published in 2003, indicate that acquired hemophilia usually develops postpartum, after a median of 60 days after delivery [11] . In the EACH2 Registry, acquired hemophilia was detected within 7 to 355 days (interquartile range [IQR] 21-120 days) (a median of 89 days) after delivery and the most common bleeding pattern was extensive subcutaneous hemorrhages (45%), mucosal bleeding (43%), intramuscular hematomas or retroperitoneal hemorrhage (33%). Only 2 women experienced bleeding into the joints [12] . In 45% of women bleeding was spontaneous, and in 55% it occurred after trauma [12] . Post-traumatic bleeds were predominantly peripartum (34% of all bleeds), and postsurgical (9% of all bleeds) [12] . Importantly, out of the 42 women included into the EACH2 Registry, in 8 (19%) the symptoms of AHA were present antepartum [12] . Data from the EACH2 Registry reveal a significant delay in final diagnosis of pregnancy-associated and postpartum AHA. The median time between the first symptoms of abnormal bleeding and the diagnosis of AHA was 6 days (in every fourth women it was 21 days) [12] .
Based on published data from about 20 years ago, it can be assumed that in about 70% of women with pregnancy-associated/postpartum AHA the spontaneous remission of the disease can be expected [13, 14] . However, in the case of no remission and a severe course of bleeding disorder, an appropriate hemostatic and immunosuppressive treatment should be administered. In the EACH2 Registry, 39 out of 42 women with the pregnancy-associated or postpartum AHA required immunosuppressive treatment [12] . In the opinion of some of clinicians, eradication of the FVIII inhibitor with a use of immunosuppressive drugs in postpartum acquired hemophilia A is often more difficult than in the idiopathic AHA or in AHA with other underlying conditions [7] . This opinion contradicts the results of the EACH2 Registry, which show that the use of corticosteroid monotherapy led to the eradication of FVIII inhibitor in 74% of women with pregnancy-associated AHA, i.e. at no lesser percentage than in other groups of AHA patients [12] .
In the EACH2 Registry, the primigravida accounted for 74% of all women who developed AHA associated with pregnancy and delivery [12] . Additionally, all women with pregnancy-associated or postpartum AHA in the EACH2 Registry were free of other serious diseases or clinical conditions Requiring no hemostatic treatment 20 that could explain the occurrence of AHA [12] . These data are consistent with the results of previous studies. The final assessment of the health status in women with pregnancy-associated or postpartum AHA, in the EACH2 Registry follow-up was performed at a median of 406 days (IQR 221-817 days) from the onset of AHA symptoms [12] . At that time, all women were alive and 36 out of 42 (86%) achieved complete remission. These results confirm a better prognosis in women with pregnancy-associated or postpartum AHA as compared to women with AHA associated with other underlying conditions. [12] . The EACH2 registry does not provide information on subsequent pregnancies in this group of 42 women. One paper describes a decrease in the FVIII activity in the blood of a neonate born to a woman with AHA, following transplacental transfer of FVIII antibodies [15] .
In the newborn occurred a hemorrhage requiring hemostatic treatment.
LABORATORY FINDINGS
In a person with AHA, laboratory tests typically show a 2-3-fold prolongation of activated partial thromboplastin time (aPTT) with normal prothrombin time (PT), thrombin time (TT), closure time (CT) in PFA-100/-200® (platelet function analyzer), normal platelet count and the plasma fibrinogen level within the normal range (Tab. 3). Such a combination of laboratory test results is also found only in congenital deficiency of clotting factors VIII, IX, XI, XII and in the presence of lupus anticoagulant (LA) in the test plasma. However, LA is not directed against the clotting factor but against phospholipids and does not trigger bleeding but predisposes to thrombosis. If prolonged aPTT is caused by a presence of unfractionated heparin in the blood sample, the thrombin time is significantly prolonged or non-determinable. Confirmation of the presence of circulating anticoagulant is prolonged aPTT in a mixture of equal volumes of the tested plasma and normal plasma (no aPTT correction, i.e. a positive test for the presence of circulating anticoagulant). A test for the presence of circulating anticoagulant is positive with either FVIII inhibitor or LA or an inhibitor directed against coagulation factors other than FVIII. Therefore, factor VIII activity should be measured, to confirm that the circulating anticoagulant is directed against FVIII. FVIII activity in healthy individuals is comprised in the range of 50-150 IU/dL (50-150% of the normal), while in AHA it is in the range of 0-20 IU/dL. The last step to the laboratory diagnosis of the presence of FVIII inhibitor is a measurement of its titer expressed in Bethesda units (BU/mL) [16] [17] [18] . It is worth emphasizing that laboratory diagnostics for the FVIII inhibitor should be carried out in blood samples taken before initiation of hemostatic treatment (see below). Following administration of hemostatic agent, some patients with AHA shorten or even normalize aPTT, which falsifies the results of subsequent laboratory tests and may lead to erroneous exclusion of AHA as a cause of hemorrhage (Fig. 2) .
As the diagnostic process of AHA combines the analysis of the clinical presentation and the results of specialistic laboratory tests, the authors of this paper indicate the need for close cooperation between the medical team and the laboratory diagnostics team in order to optimize this process.
MANAGEMENT
The treatment strategy in patients with acquired hemophilia A has two main goals: immediate, which is control and prophylaxis of bleeding, and the ultimate one, which is inhibitor eradication i.e. complete remission of AHA, often meaning the cure (Fig. 2) . In rare cases of AHA without accompanying symptoms of bleeding disorder, the management will be limited to the elimination of the inhibitor. Prompt diagnosis and appropriate treatment of comorbidities may increase the chance to achieve AHA remission.
HEMOSTATIC AGENTS
Unlike congenital hemophilia A, there is no close correlation between plasma FVIII activity and the severity of bleeding in AHA. Therefore, even with a very low inhibitor titer and a few to dozen percent of residual FVIII plasma activity, the best way to stop bleeding in AHA is the use of so-called by-passing agents (BPA), i.e. recombinant activated factor VII (rFVIIa) or activated prothrombin complex concentrate (aPCC), but not the administration of human factor VIII products (hFVIII) (Tab. 4). The BPA activate blood clotting, bypassing the factor VIII-dependent stage, hence their name: bypassing agents. The efficacy of rFVIIa and aPCC in control of bleeding in acquired hemophilia A has been confirmed by the results of clinical trials [1, [19] [20] [21] [22] [23] [24] . The greatest disadvantage of both drugs is the lack of laboratory tests to assess their efficacy. The risk of thrombotic complications of both drugs should not be neglected, especially in elderly people with concomitant risk factors for venous thromboembolism (VTE) and/or arterial thromboembolism (ATE). Once the remission is achieved, i.e. the inhibitor is eliminated, the use of BPA should be immediately discontinued. Anticoagulants are contraindicated in patients with AHA, however, after elimination of the inhibitor, they can be safely used if needed.
In case of a lack of clinical efficacy of rFVIIa and aPCC monotherapies, alternating rFVIIa and aPCC (so-called sequential therapy) may be used. Sequential therapy exposes patients to the risk of thromboembolic complications. Therefore, it should be only used by a hematologist experienced in the treatment of patients with bleeding disorders [25, 26] .
Recently, a new medication for bleeding control in AHArecombinant porcine factor VIII (rpFVIII) has been introduced [27, 28] . This agent shows the coagulation activity similar to human FVIII, and at the same time, in most cases is not neutralized by the antibodies against human FVIII. The biggest advantage of rpFVIII as compared to rFVIIa and aPCC is the availability of laboratory testing of factor VIII activity in plasma of AHA patients and possibility to adjust rpFVIII dose based on the results of these measurements. Before switching from BPA to rpFVIII, the plasma of the AHA patient should be tested for the presence of cross-reactive antibodies, that neutralize both hFVIII and rpFVIII. If such antibodies are present, very high doses of rpFVIII must be administered and it should be ensured that adequate (hemostatic) FVIII activity in the plasma has been reached. At the high titer of anti-porcine FVIII antibodies, the use of rpFVIII may not be effective. In Poland rpFVIII has been approved by regulatory authorities, but so far it is not reimbursed by the National Health Fund (NFZ).
In exceptional cases of AHA with a low titer of FVIII inhibitor and with a mild bleeding, the use of human FVIII concentrate or desmopressin under control of plasma FVIII activity may be effective (it is usually recommended to maintain FVIII activity above 50 IU/dL). Data from the EACH2 Registry indicate that BPA control bleeding much more effectively as compared to hFVIII concentrate and desmopressin [2, 27, 29, 30] .
The drug that effectively controls mucosal bleeding is tranexamic acid (TxA). In adults, it is administered at a dose of 1.0 g every 8 hours, orally or intravenously (local administration is less common). The drug is contraindicated in people with active bleeding from urinary tract due to the risk of clot formation and block of urine outflow. In AHA, tranexamic acid has a status of a supportive treatment. It can be used concomitantly with rFVIIa, aPCC, hFVIII and rpFVIII. The previously raised concerns about a significant increase in the risk of thromboembolic complications in patients receiving simultaneously aPCC and TxA have been dispelled after publication of positive experiences from several research teams [31, 32] .
Another treatment option used in AHA patients is the immunoadsorption combined with intravenous transfusion of high doses of hFVIII concentrate under the control of plasma FVIII activity [2] . According to the knowledge of the authors of this paper, no immunoadsorption procedures are performed in Poland, and literature data indicate that this therapeutic option is available in only a few centers in Europe [2] .
Therapeutic management for bleeding control in a woman with peripartum AHA is the same as in the other groups of AHA patients. Data from the EACH2 Registry showed high efficacy of BPA in bleeding control in the course of AHA associated with pregnancy and delivery [12] .
Although, according to the EACH2 Registry data, BPA can effectively stop bleeding in more than 93% of patients with AHA, it is recommended to avoid elective invasive pro- Figure 2 . Algorithm for management of acquired hemophilia A [10] aPCC -activated prothrombin complex concentrate; aPTT -activated partial thromboplastin time; hFVIII -human FVIII; FVIII -factor VIII; rFVIIa -recombinant activated factor VII; rpFVIII -recombinant porcine factor VIII; *) rFVIIa, aPCC, hFVIII and DDAVP concentrates are available free of charge for patients with a confirmed diagnosis of AHA in Regional Blood Donation and Transfusion Centres (RCKiKs); the list of RCKiK in Poland is included in the Supplement 2 to this paper 
INHIBITOR ERADICATION
In order to eliminate autoantibodies against FVIII, immunosuppressive drugs are used [2, 9, 11, 27, 29, 30, 34] . Immunosuppressive treatment should be initiated as soon as the diagnosis of acquired hemophilia A is confirmed, although the possible contraindications to this type of treatment should never be ignored. It also should not be forgotten that immunosuppressive therapy carries a considerable risk of side effects, including myelosuppression and serious infections, which are particularly dangerous in the elderly patients, who constitute the majority of patients with acquired hemophilia A. Nonetheless, in the EACH2 Registry, also three young women with pregnancy-associated or postpartum AHA developed complications after immunosuppression -two patients had post-steroid diabetes, and one suffered from infection [12] .
The majority of authors recommends corticosteroids or corticosteroids with cyclophosphamide in the first-line of immunosuppressive therapy (Tab. 5) [1, 2, 9, 11, 27, 29, 30, [34] [35] [36] [37] [38] [39] . There is usually given prednisone/prednisolone orally at a dose of 1 mg/kg/day for 4-6 weeks in monotherapy or in combination with cyclophosphamide also orally at a dose of 1-2 mg/ kg/day, for a maximum of 6 weeks. With the use of such treatment regimen remission, defined as an increase in FVIII activity above 50 IU/dL and lowering the inhibitor titer below the detection threshold, i.e. 0.6 BU/mL, is achieved in about 70% of patients. In the EACH2 Registry, at the end of follow-up, after a median of 258 days (IQR 74-685 days) 72.6% of patients with AHA achieved complete remission of disease, 11.8% of patients normalized FVIII activity, but continued immunosuppressive therapy, 10% of patients failed to eliminate FVIII inhibitor, and in 6.6% of patients the status of FVIII inhibitor was unknown [1] .
In patients who have not achieved remission after 4-6 weeks of immunosuppressive treatment, a second attempt to eliminate the inhibitor is recommended. Currently, the prevailing opinion is that in the second-line of immunosuppressive treatment it is worth using rituximab at a standard dose of 375 mg/m2/week for the consecutive 4 weeks (smaller doses have also been successfully used) [40, 41] . Unfortunately, the use of rituximab in patients with AHA is not covered by the NFZ reimbursement in Poland. Other therapeutic options include the use of ciclosporin, tacrolimus, azathioprine, vincristine and mycophenolate mofetil, as well as a combination therapy including several immunosuppressants administered concomitantly, e.g. cyclophosphamide + vincristine + prednisone [42] [43] [44] [45] [46] . In the opinion of some investigators, the combined use of immunosuppressive drugs and intravenous injections of hFVIII concentrate contributes to the shortening of time needed to eliminate the inhibitor. This treatment regimen, elaborated by the Hungarian authors and based on the immunotolerance programs used in congenital hemophilia A with alloantibodies developed against FVIII, is referred to as the Budapest Program (Tab. 5) [47] . The management targeted on elimination of FVIII inhibitor in a woman with the postpartum AHA is based on the same principles as in the other groups of AHA patients with one exception; in young patients at childbearing age, the use of cytotoxic drugs (e.g. cyclophosphamide) is avoided [2, 12] . Data from the EACH2 Registry showed a high efficacy of immunosuppressive drugs (including corticosteroid monotherapy) in eliminating FVIII inhibitor in AHA associated with pregnancy and delivery [12] .
FOLLOW-UP AFTER COMPLETE REMISSION
After achieving remission, the patient should be followed-up for two years for possible relapse [2, 27, 29, 30] . FVIII activity should be measured once a month for the first six months after remission, then every 2-3 months for the next six months and then every 6 months for the following year. It is estimated that AHA relapse occurs in about 20% of patients who achieved remission after the first course of immunosuppressive treatment [5] . In such cases, second attempt to eliminate the inhibitor should be taken and the same immunosuppressive treatment that provided the first remission can be used. If immunosuppressive therapy completely fails, a careful monitoring and treatment of hemorrhage is the only management option. In case of high severity of bleeding disorder, prolonged prophylaxis with use of inhibitor bypassing agents can be considered [23, 48] .
Older studies did not show AHA recurrence in subsequent pregnancies, but recently such cases have been described [14, [49] [50] [51] . Therefore, if a woman with a history of pregnancy-associated or postpartum AHA is planning another pregnancy, she should be covered by a specialist care of gynecologist and hematologist, to ensure monitoring of hemostasis system for prompt detection of FVIII inhibitor recurrence.
PROGNOSIS FOR SURVIVAL IN ACQUIRED HEMOPHILIA A
Prognosis in AHA depends on the type and course of comorbidities, on the severity of bleeding and on the time to diagnosis and initiation of appropriate anti-hemorrhagic and immunosuppressive treatment [30] .
In the EACH2 Registry, the survival analysis included a group of 331 patients with AHA. The median follow-up was 258 days (IQR 74-685 days). The final analysis showed that 61.2% of patients survived, 27.9% died, with a median of time between AHA diagnosis and death being 75 days (IQR 25-240 days). For 10.9% of patients the survival status remained unknown [1] . Data from this registry identified the independent risk factors for death in AHA patients: older age, lower hemoglobin level at the AHA diagnosis, concomitant malignancy, and failure to eliminate FVIII inhibitor [1] . In contrast, gender, FVIII activity at the time of AHA diagnosis and FVIII inhibitor titer at the time of AHA diagnosis did not show a statistically significant effect on the patients' survival [1] . Death due to a bleeding occurred in 3% of patients followed in the EACH2 Registry [1] . Interestingly, excessive bleeding was the cause of (only) 16% of all deaths in the analyzed group. The most frequent cause of death in this group was underlying disease, responsible for 45% of all deaths (9% of patients in the follow-up of the EACH2 Registry). Complications of immunosuppression, similarly to hemorrhages, were responsible for deaths of 3% of all patients followed in the EACH2 Registry.
SUMMARY
The cardinal principles of diagnostic and therapeutic approach in AHA are presented below: 1. A sudden onset of bleeding disorder accompanied by an isolated prolonged aPTT in a person with no previous history of bleeding should raise a suspicion of acquired hemophilia A. 2. Acquired hemophilia A affects, most of all, elderly people and patients with autoimmune diseases or malignancies, but young women up to 12 months after delivery are also at higher risk of developing AHA. 3. In young women diagnosed with autoimmune disease, the possibility of occurrence of AHA in the peripartum period should be taken into consideration and a patient should be offered a care of the facility capable to monitor hemostasis system throughout a pregnancy, delivery and postpartum period. 4. Irrespective of age, in women with autoimmune disease and malignancy that experience prolonged uterine or vaginal bleeding, the possibility of AHA should be considered and basic coagulation tests should be done. Once the isolated prolonged aPTT is found, the diagnostic panel for AHA should be conducted. 5. Although AHA is classified as a severe bleeding disorder, in about 30% of cases the symptoms of the disease are occult or scarce, which may hinder establishing promptly a proper diagnosis. 6. Laboratories of hemostasis should develop and apply in their daily practice the algorithms for detection of isolated prolonged aPTT. This algorithms should include the clinical presentation (presence or absence of symptoms of bleeding disorder) and the mixing test of examined and normal plasma for an aPTT correction, which indicates the presence or absence of a circulating anticoagulant. 7. Invasive procedures and surgical operations expose AHA patients to the risk of uncontrolled hemorrhage, even when using appropriate hemostatic drugs at proper doses. Therefore, it is recommended to avoid all elective invasive procedures in this group of patients until the FVIII inhibitor is eliminated. If a delay in invasive procedure is not possible, the anti-hemorrhagic management should be decided by a hematologist experienced in the treatment of bleeding disorders. 8. The strategy for management of AHA patient includes bleeding control, elimination of FVIII inhibitor and treatment of comorbidities, first of all those that predispose to a development of FVIII inhibitor. 9. The first-line hemostatic drugs are inhibitor bypassing agents, i.e. rFVIIa and aPCC. Desmopressin and human factor VIII concentrate are less effective than bypassing agents. Recombinant porcine factor VIII is not reimbursed by National Health Fund in Poland. Tranexamic acid is a supportive drug. Posology of hemostatic drugs is shown it the Table 4 . 10. In case of a lack of clinical efficacy of rFVIIa and aPCC monotherapies, alternating rFVIIa and aPCC (so-called sequential therapy) may be used. Sequential therapy exposes patients to the risk of thromboembolic complications. Therefore, it should be only used by a hematologist experienced in the treatment of patients with bleeding disorders. 11. The FVIII inhibitor should be eliminated by using immunosuppressive drugs in every patient with AHA (unless the inhibitor has been eliminated spontaneously). Immunosuppressive treatment should be initiated as soon as possible after the AHA is diagnosed, provided there are no contraindications to this therapy. 12. In the first-line of immunosuppressive treatment, corticosteroids are used, most often prednisone/prednisolone orally at a dose of 1 mg/kg/day. Sometimes prednisone/prednisolone is used in combination with cyclophosphamide from the very beginning of treatment, however the latter one should not be administered in patients at childbearing age. In the second-line treatment for elimination of FVIII inhibitor in AHA rituximab is the most commonly prescribed drug; unfortunately, in this indication rituximab is not covered by the NFZ reimbursement. Posology of immunosuppressive drugs used in the treatment of AHA patients is shown in Table 5 . 13. Care for a woman with pregnancy-associated or postpartum AHA should be taken by a team consisting of a gynecologist-obstetrician and a hematologist experienced in the treatment of patients with bleeding disorders. 14. The principles of treatment of a woman with pregnancy-associated and postpartum AHA do not differ from the principles of treatment in other groups of patients with AHA. This applies to the use of both hemostatic and immunosuppressive drugs. The only exception is the avoidance of cyclophosphamide and other alkylating drugs in women at childbearing age. 15. The AHA may recur, therefore, after successful FVIII inhibitor elimination, aPTT and plasma FVIII activity should
